ClinicalTrials.gov
public full text
Public Domain
A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)
This is a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical study evaluating the efficacy and safety of IBI362 in MASH subjects. Subjects will be randomly assigned to IBI362 low-dose, high-dose and placebo groups. The entire trial cycle includes a 8-week screening period, a 60-week double-blind treatment period, and a 4-week follow-up period.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)#895892
- A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001)#1060729
- A Study of IBI362 9 mg in Chinese Adults With Obesity#918209
- Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)#802916
- Observational Study About Patients Diagnosed With NAFLD#890417
Record · ID 1351969
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive